Clinical Medicine Research

Special Issue

Combination Therapy in Bladder Cancer

  • Submission Deadline: 9 August 2024
  • Status: Submission Closed
  • Lead Guest Editor: Weigang Ren
About This Special Issue
Bladder cancer is a common and challenging tumor, and the effectiveness and side effects of traditional treatment methods have always been a difficult problem faced by patients and doctors. However, recent studies have shown that combination therapy of immunotherapy and chemotherapy may change the treatment landscape of bladder cancer, providing better treatment outcomes and quality of life for patients.
This special issue aims to gather the latest research findings and clinical practice experiences from the academic community, both domestically and internationally, in the field of combination therapy of immunotherapy and chemotherapy in bladder cancer. Within this topic, we warmly welcome submissions in basic science research, clinical research, bioinformatics research, and review articles, with an emphasis on novel technologies and theories. We hope this topic can provide new biomarkers for cancer immunotherapy resistance, elucidate potential mechanistic pathways, and provide compelling evidence for overcoming this process in clinical applications. We encourage submissions covering the following research topics:
(1) The fundamental principles and mechanisms of immunotherapy and chemotherapy
(2) Strategies for the combination therapy of immunotherapy and chemotherapy in bladder cancer treatment
(3) Evaluation of the therapeutic efficacy and clinical practice results of immunotherapy and chemotherapy
(4) Applications and prospects of personalized treatment in combination therapy of immunotherapy and chemotherapy
(5) The potential of combination therapy of immunotherapy and chemotherapy in bladder cancer prevention and recovery
(6) Applications of combination therapy of immunotherapy and chemotherapy in specific subtypes and stages of bladder cancer
(7) Management of side effects and safety evaluation in combination therapy of immunotherapy and chemotherapy

Keywords:

  1. Bladder Cancer
  2. Immunotherapy
  3. Chemotherapy
  4. Combination
  5. Therapy
  6. Personalized Treatment
  7. Efficacy Evaluation
  8. Future Directions
Lead Guest Editor
  • Weigang Ren

    Department of Urology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, China

Guest Editors
  • Xin Jin

    Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, China

  • Wei Xiong

    Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, China

  • Mou Peng

    Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, China

  • Liang Zhu

    Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, China

  • Yunliang Gao

    Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, China

  • Lu Yi

    Department of Urology, The Second Xiangya Hospital, Central South University, Changsha, China